Research report on US Alzheimer drug market

Published on October 29, 2013 at 8:58 AM · No Comments

US Alzheimer Drug Pipeline Analysis 2013 market research report gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. Complete report is available at .

Global Cell Therapy Pipeline Analysis 2013 market research report gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Cell Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the Cell Therapy associated with the various diseases. Complete report is available at .

In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer's disease was 5.4 million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at least 200,000 patients were younger than 65 with early onset of Alzheimer's. It has been observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer's disease. Amongst the population in the 80+ age group, almost 45% have been detected with Alzeimer's disease.

There exists strong competition in the Azheimer's disease market in the US. Due to this, the market is open to new and savvy companies. Given that there is a continuous rise in the ageing population and an expected exponential increase in Alzheimer's disease cases, these new entrants have the opportunity to capture a major share in the market through their efficient therapies and drugs. Thus, a better understanding of the underlying biology by the new entrants would lead to many new branches of treatment in different stages of clinical testing.

Following parameters for each drug profile in development phase are covered in "US Alzheimer Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

US Alzheimer Drug Pipeline by Clinical Phase:

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment